Editas Medicine, Inc.·4

Jul 25, 4:45 PM ET

Burkly Linda 4

4 · Editas Medicine, Inc. · Filed Jul 25, 2023

Insider Transaction Report

Form 4
Period: 2023-07-24
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Transactions
  • Award

    Stock Option (right to buy)

    2023-07-24+135,500135,500 total
    Exercise: $8.66Exp: 2033-07-23Common Stock (135,500 underlying)
  • Award

    Common Stock

    2023-07-24+45,16745,167 total
Footnotes (2)
  • [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on July 24, 2024 continuing through July 24, 2027.
  • [F2]This option was granted on July 24, 2023 and is scheduled to vest over four years, with 25% of the shares to vest on July 24, 2024 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 24, 2027.

Documents

1 file
  • 4
    form4-07252023_040701.xmlPrimary